These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 16678059)
1. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Ryan CJ; Lin AM; Small EJ Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059 [TBL] [Abstract][Full Text] [Related]
3. Angiogenesis as a strategic target for prostate cancer therapy. Li Y; Cozzi PJ Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866 [TBL] [Abstract][Full Text] [Related]
4. The use of thalidomide in androgen-independent prostate cancer. Cox MC; Dahut WL; Figg WD Urol Oncol; 2006; 24(3):246-9. PubMed ID: 16678058 [TBL] [Abstract][Full Text] [Related]
5. New drugs in prostate cancer. Armstrong AJ; Carducci MA Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849 [TBL] [Abstract][Full Text] [Related]
6. Management of hormone refractory prostate cancer. Lin AM; Small EJ Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361 [TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and anti-angiogenic therapy in prostate cancer. Mukherji D; Temraz S; Wehbe D; Shamseddine A Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349 [TBL] [Abstract][Full Text] [Related]
8. The role of systemic cytotoxic therapy for prostate cancer. Chang SS; Kibel AS BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524 [TBL] [Abstract][Full Text] [Related]
9. Novel targets and approaches in advanced prostate cancer. Hadaschik BA; Sowery RD; Gleave ME Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516 [TBL] [Abstract][Full Text] [Related]
10. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Lin AM; Ryan CJ; Small EJ Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610 [TBL] [Abstract][Full Text] [Related]
11. Brain metastases in hormone refractory prostate cancer: a changing natural history? Roberts-Thomson R; Rosenthal MA; Gonzales M; Drummond K Intern Med J; 2009 Mar; 39(3):205-6. PubMed ID: 19383072 [No Abstract] [Full Text] [Related]
12. The present and future of angiogenesis-directed treatments of colorectal cancer. O'Dwyer PJ Oncologist; 2006 Oct; 11(9):992-8. PubMed ID: 17030640 [TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic strategies for cancer therapy (Review). Benouchan M; Colombo BM Int J Oncol; 2005 Aug; 27(2):563-71. PubMed ID: 16010440 [TBL] [Abstract][Full Text] [Related]
14. Cancer and Leukemia Group B trials for advanced prostate cancer. Small EJ; Dawson NA; Kantoff PW; Vogelzang NJ Semin Oncol; 1996 Dec; 23(6 Suppl 14):28-31. PubMed ID: 8996582 [TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitors in prostate cancer therapy. Yu EM; Jain M; Aragon-Ching JB Discov Med; 2010 Dec; 10(55):521-30. PubMed ID: 21189223 [TBL] [Abstract][Full Text] [Related]
16. Angiogenesis inhibitors in the treatment of prostate cancer. Adesunloye BA; Karzai FH; Dahut WL Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611 [TBL] [Abstract][Full Text] [Related]
17. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Oh WK; Tay MH; Huang J Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531 [TBL] [Abstract][Full Text] [Related]
19. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Roy V; Perez EA Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790 [TBL] [Abstract][Full Text] [Related]